InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,242.00
(
0.05%
)
Dow Jones
39,872.99
(
0.00%
)
Brent Oil
81.87
(
-0.70%
)
Bitcoin
69,988.47
(
-0.20%
)
Post# of 251889
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: dewophile post# 168108

Tuesday, 10/15/2013 10:30:38 AM

Tuesday, October 15, 2013 10:30:38 AM

Post# of 251889

there is some compelling data for competing companies expected at AASLD. In particular GILD BMY and perhaps MRK may have early data on viable regimens without ribavirin.

I am quite certain you don't need the word 'perhaps' in conjunction with MRK's C-WORTHY (MK-5172 in combination with MK-8742 ± ribavirin) Study data.

http://www.natap.org/2013/HCV/100313_01.htm
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up